HealthPolitics

STAT+: Forbion raised $2.6 billion, marking its largest fundraise to date.

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 07/10/2026, 21:21:26 UTC.

Briefings

STAT released its 2026 Wunderkinds list on October 7, 2026, identifying early-career researchers in health and medicine. The briefing highlights Cerevance's experimental pill Solengepras, which reduced Parkinson's patients' daily off-time in a Phase 3 trial, and notes Henri B. Kagan and Kenso Soai's 2026 Nobel Prize in chemistry for manipulating mirror image molecules. It also reports that Doudna-founded Caribou Biosciences is shutting down after failing to secure funding for a late-stage CAR-T therapy trial for lymphoma.

Key points

• Cerevance's Solengepras reduced Parkinson's patients' daily off-time in a Phase 3 trial, with the company now discussing potential regulatory approval.
• Henri B. Kagan and Kenso Soai were awarded the 2026 Nobel Prize in chemistry for discovering how to manipulate mirror image molecules.

Context and limitations

This briefing covers only the 2026 Wunderkinds list and specific recent developments in biotech funding and research. It does not include historical data, long-term outcomes, or future predictions beyond the reported trial results.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 08/10/2026, 10:59:32 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeib3rjei65lvvck3tpdbrsmjhfiur2ovjyocoqm67xfpi4zx6cqmwy